Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
05 Outubro 2023 - 10:15AM
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company
committed to the treatment of Alzheimer’s disease dementia, today
announced that Remi Barbier, President & Chief Executive
Officer, is invited to present at the Jefferies Biotech CNS/Neuro
Summit in New York on Wednesday, October 11, 2023 at 10:30am ET. A
live webcast and archived replay will also be available.
Live
Webcast: https://wsw.com/webcast/jeff292/sava/1848712
Archived Replay:
https://www.CassavaSciences.com/company-presentations
In addition, Eric Schoen, Cassava Sciences’
Chief Financial Officer, will attend the JonesTrading 2023
Healthcare Summit in Miami on October 10-11th.
About Cassava Sciences,
Inc.Cassava Sciences is a clinical-stage biotechnology
company based in Austin, Texas. Our mission is to detect and treat
neurodegenerative diseases, such as Alzheimer’s disease. Cassava
Sciences is evaluating its lead drug candidate, oral simufilam, for
Alzheimer’s disease dementia in two global, ongoing Phase 3
clinical studies. Our novel science is based on stabilizing—but not
removing—a critical protein in the brain. Our product candidates
have not been approved by any regulatory authority, and their
safety or efficacy have not been established in humans. For more
information, please visit: https://www.CassavaSciences.com
For More Information Contact: Eric Schoen,
Chief Financial Officer(512) 501-2450 or
ESchoen@CassavaSciences.com
Cassava Sciences (NASDAQ:SAVA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cassava Sciences (NASDAQ:SAVA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024